Top 6: What is EU HTA and why should statisticians care?
Interview with Lara Wolfson and Anders Gorst-Rasmussen
The Effective Statistician - in association with PSI
Audio is streamed directly from the publisher (audio.podigee-cdn.net) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Why You Should Listen:
✔ EU HTA is becoming reality: Joint Clinical Assessments begin soon with oncology/ATMPs and will expand to all medicines over the next years.
✔ Statisticians are central: Re-analyses, indirect comparisons, RWE, and quality-of-life analyses will be required—often beyond what regulatory trials were designed for.
✔ Timelines are tight: From EMA Day 120 scoping to dossier deadlines and final JCAs just 30 days post-marketing authorization.
✔ Transparency and resources matter: Joint assessments will be public, and both companies and agencies face capacity and clarity challenges.
✔ You can prepare now: Incorporate HTA needs into trial design, analysis planning, and cross-functional collaborations.
Episode Highlights:
00:00 – 02:30 | I introduce the episode and explain why EU HTA is such a critical topic
02:30 – 05:30 | Lara and Anders introduce themselves and their HTA work at MSD and Novo Nordisk
05:30 – 10:45 | Regulatory vs. HTA: safe & effective vs. how good, for whom, and at what cost
10:45 – 18:30 | Europe’s patchwork: national differences in comparators, standards of care, and access
18:30 – 23:45 | The EU regulation: joint clinical assessments, economic modeling, and what’s changing
23:45 – 32:30 | What it means for us as statisticians: re-analyses, ITCs/NMAs, RWE, QoL, and capacity issues
32:30 – 36:00 | Why “transparency” can’t just be 50,000-page PDFs—clear, reproducible evidence matters
36:00 – 45:00 | The PSI HTA SIG’s role, current activities, and how you can get involved
45:00 – end | Our final takeaways and a call for statisticians to engage now
Links:
🔗 Join the PSI HTA Special Interest Group and watch for their newsletter and training.
🔗 Review EUnetHTA 21 methodological drafts—they are shaping the future of JCAs.
🔗 The Effective Statistician Academy – I offer free and premium resources to help you become a more effective statistician.
🔗 Medical Data Leaders Community – Join my network of statisticians and data leaders to enhance your influencing skills.
🔗 My New Book: How to Be an Effective Statistician - Volume 1 – It’s packed with insights to help statisticians, data scientists, and quantitative professionals excel as leaders, collaborators, and change-makers in healthcare and medicine.
🔗 PSI (Statistical Community in Healthcare) – Access webinars, training, and networking opportunities.
Join the Conversation:
Did you find this episode helpful? Share it with your colleagues and let me know your thoughts! Connect with me on LinkedIn and be part of the discussion.
Subscribe & Stay Updated:
Never miss an episode! Subscribe to The Effective Statistician on your favorite podcast platform and continue growing your influence as a statistician.
Glossary:
HTA – Health Technology Assessment
EU HTA / JCA – Joint Clinical Assessment forming the evidence base for national HTA decisions
EMA / CHMP – European Medicines Agency / Committee for Medicinal Products for Human Use
RWE – Real-World Evidence; NMA/ITC – Network/Indirect Treatment Comparison
QoL/HRQoL – (Health-Related) Quality of Life measures
PSI HTA SIG – PSI Special Interest Group on HTA
EFPIA – European Federation of Pharmaceutical Industries and Associations
